Alkem Laboratories FY26: Record Profits, Semaglutide Sprint, Occlutech Bet
General information and entertainment, not investment advice. The author is not a SEBI-registered adviser or research analyst. No recommendation, no promised returns. Markets carry risk including loss of capital. Figures may not be current. Consult a registered adviser before acting.
1. At a Glance
Alkem closed FY26 with its highest annual net profit on record—₹2,302 crore, up 6.3% from ₹2,165 crore in FY25. Revenue climbed 13.5% to ₹14,712 crore. EBITDA crossed ₹3,000 crore for the first time, with margin expanding from 19.4% to 20.4%.
The domestic branded generics business grew 9.7%, slower than headline revenue, because of a transitional restructuring in trade generics (the lower-margin channel). Internationally, the business grew 22.5%, held back by the crore-heavy decision to bet EUR 99 million (~₹1,100 crore) on Occlutech, a Swiss heart-device maker. A semaglutide launch in March 2026 claimed 11% market share within weeks.
The tension: margin has finally broken north, the chronic therapy mix is shifting upward, but the company has just committed a year’s operating cash flow to a non-pharma acquisition while defending against tax scrutiny and positioning for leadership transition.
The question: does a 21.2% ROCE justify a 26.4x P/E when the company is no longer purely pharmaceutical?
2. Introduction
Alkem is the fifth-largest pharmaceutical company in India by market share (4.1% as of 9M FY25), with the #1 position in anti-infectives and top-3 spots in GI, pain, and vitamins/minerals/nutrients. It has 17 brands exceeding ₹1 billion in annual sales, including three “mega brands” above ₹5 billion. The distribution network spans 12,500+ field force, 9 central warehouses, 75+ depots, and 8,400+ stockists—the second-largest network in the country.
In February 2026, Alkem announced a binding offer to acquire 51–55% of Occlutech Holding AG, a Switzerland-based structural heart device company, for EUR 180.7 million (valued at ~₹1,952 crore equity). The transaction is expected to close within 45–60 days from the concall (early June 2026), funded entirely from cash on hand.
In March 2026, CEO Dr. Vikas Gupta resigned; his tenure closes on 30 June 2026 to allow a transition. The board is conducting a search using “top 3 global head-hunters.”
On 2 June 2026, Alkem launched semaglutide pre-filled syringes in a single-shot weekly format at ₹350 after DCGI approval, priced 80% below the innovator. Within weeks, market share in the GLP-1 segment climbed to 11% unit share per IQVIA, positioning it as a material growth vector for FY27.
3. Business Model: WTF Do They Even Do?
Alkem manufactures and sells branded and generic pharmaceuticals domestically, exports generics and biosimilars internationally, and operates contract manufacturing for biologics. The three segments are domestic (70% of revenue), international (30%), and emerging non-pharma (Occlutech, Enzene, MedTech—currently immaterial).
Domestic: Acute Dominance, Chronic Acceleration
The domestic business derives over 80% of revenue from acute therapies: anti-infectives (rank 1), pain (rank 3), and GI (rank 3). These categories are slower-growing and price-controlled. Chronic therapies—anti-diabetes, cardiology, neurology, respiratory, dermatology—now contribute close to 22% of branded generics, up 1% annually over four years.
Semaglutide enters this chronic ramp as a high-ticket new product. Management flagged it as “one of the biggest priorities” for FY27. The launch reached 11% market share in unit sales within three weeks, suggesting either effective market access or meaningful unmet demand or both.
The trade generics channel (below-brand generics sold through drugstore chains) contributed softer growth at 4.3% in FY26, a deliberate de-prioritization to lock down receivables and margin. This carveout as a separate entity means the reported number masks underlying profitability.
The company operates in 80 countries with 10+ out-licensing agreements for 7 biosimilars (denosumab, romosozumab and others). The US remains the largest international market, driven by 154 approved ANDAs out of 179 filed. Growth in high-single-digits is structural—new launches offset “value erosion” on existing products, a euphemism for pricing pressure and patent cliffs.
Denosumab (a Prolia/Xgeva biosimilar) approval is progressing in the US, potentially by Q1 FY27, but the company flagged it has “no basket yet,” meaning limited market access. Europe has a “partner” only for one indication, implying other markets await out-licensing. This constraint—a narrow portfolio and dependence on partners—limits upside velocity.
Enzene (US CDMO): Ramp Loss-Making
Enzene Biosciences, Alkem’s biologics/CDMO subsidiary, is profitable in India (“teens EBITDA”) but loss-making in the US during ramp. Management expects US breakeven “maybe this year” but cautioned against extrapolating tariff headlines into immediate scaling—customer cycles are long, and large companies are still setting up in-house capacity.
US CDMO revenue last year was “less than ₹100 crore”; management targets “meaningfully ₹200–300 crore,” but this will take “a couple of years.”
Occlutech (New MedTech): Post-Close Integration
Occlutech, CY25 revenue ₹487 crore, specializes in advanced structural heart devices. The company is profitable and has FDA clearance. Alkem’s bet is geographic: Occlutech’s distribution network in Europe and semi-regulated markets can be leveraged by Alkem’s domestic field force once acquired.
Management described this as “one of our biggest investments in the last 10 years” and paused further M&A for at least 12 months to focus on integration.
4. Financials Overview
Figures are consolidated, in ₹ crore. Result Type: Yearly. Latest period: Mar 2026.
Metric
FY26
FY25
YoY
Revenue
14,712
12,965
+13.5%
EBITDA
3,005
2,512
+19.6%
PAT
2,302
2,165
+6.3%
EPS (annualised)
192.51
181.11
+6.3%
Q4 FY26 Quarterly Details (per management concall, 1 Jun 2026):
Revenue from operations: ₹3,603 crore (+14.6% YoY). EBITDA ₹517 crore, but margin compressed to 14.4% (vs. 12.4% prior year) due to non-recurring charges: ₹602.7 crore gratuity/leave encashment liability from “central loans under labour codes” and ₹747 crore real estate impairment.
Adjusted for these items, Q4 operating profit would sit higher. The concall clarified FY26 EBITDA margin was 20.4% vs. FY25’s 19.4%, and management attributed the expansion to “improving business mix, operating leverage, and continued cost discipline.”
Concall Guidance (Directional, Not Formal)
India: continue 100–150 bps above IPM growth (IPM grew ~10% in FY26; Alkem +11.1%). US (pharma): “high single-digit” growth. RoW: “higher teens” growth. R&D: expected to remain 4–5% of revenue (FY26: 4.2%, Q4 elevated at 6.4% due to filings).
5. Valuation Discussion: Fair Value Range (Educational Only)
What follows is a walkthrough of how three valuation methods work, using this company’s numbers as the example — not a target, not a forecast, not advice.
Method 1: P/E
Annualised EPS (FY26 full year): ₹192.51. Peer band for large-cap Indian pharma: 20–35x. Method 1 outputs: 192.51 × 20–35x = ₹3,850–₹6,738 per share.
Method 2: EV/EBITDA
FY26 EBITDA: ₹3,005 crore. Net cash (cash less borrowings): ₹1,733 − ₹2,047 = negative ₹314 crore (the company carries net debt). Enterprise value for large-cap pharma: 12–18x EBITDA. At 12–18x, EV ranges ₹36,060–₹54,090 crore. Less net debt of ₹314 crore, equity value: ₹35,746–₹53,776 crore, or ₹2,990–₹4,493 per share (on 12 crore shares).
Assume 12% annual revenue growth (mid-point of historical and concall guidance), 21% EBITDA margin (company target), terminal growth 3%, WACC 9%. This methodology over 5 years and perpetuity yields a per-share range of ₹3,200–₹4,800.
These figures show how the methods work and are not a valuation, a
